Design and bioactivities of melanotropic peptide agonists and antagonists: Design based on a conformationally constrained somatostatin template
Authors:
- 1 May 1998
- journal article
- Published by Springer Nature in Letters in Peptide Science
- Vol. 5 (2-3) , 117-120
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A topographical model of μ‐opioid and brain somatostatin receptor selective ligands NMR and molecular dynamics studiesInternational Journal of Peptide and Protein Research, 1995
- Design, Synthesis, Biology, and Conformations of Bicyclic .alpha.-Melanotropin AnalogsJournal of Medicinal Chemistry, 1995
- Cloning and Functional Characterization of a Family of Receptors for the Melanotropic PeptidesAnnals of the New York Academy of Sciences, 1993
- Design, Synthesis, and Conformation of Superpotent and Prolonged Acting MelanotropinsaAnnals of the New York Academy of Sciences, 1993
- PrefaceAnnals of the New York Academy of Sciences, 1993
- Design of a new class of superpotent cyclic .alpha.-melanotropins based on quenched dynamic simulationsJournal of the American Chemical Society, 1989
- Design and synthesis of somatostatin analogs with topographical properties that lead to highly potent and specific .mu. opioid receptor antagonists with greatly reduced binding at somatostatin receptorsJournal of Medicinal Chemistry, 1988
- Conformationally restricted analogs of somatostatin with high mu-opiate receptor specificity.Proceedings of the National Academy of Sciences, 1985
- [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity.Proceedings of the National Academy of Sciences, 1982
- IN VITROBIOASSAY FOR THE MELANOCYTE STIMULATING HORMONE1Endocrinology, 1954